Bessemer Group
GEVA

Bessemer Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bessemer Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-4,455
Closed -$288K – 1419
2013
Q4 		$288K Buy
4,455
+261
+6% +$15.5K ﹤0.01% 618
2013
Q3 		$267K Hold
4,194
– – ﹤0.01% 624
2013
Q2 		$176K Buy
+4,194
New +$191K ﹤0.01% 580

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bessemer Group's GEVA Position: Q1 2014 in Review

Bessemer Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2014, closing a stake of 4,455 shares — an estimated $288K sold.

Bessemer Group first reported a position in GEVA in Q2 2013 and held it in 3 quarters. The position peaked at $288K in Q4 2013. 115 funds tracked by Wall St. Rank hold GEVA as of Q1 2014.

  • Bessemer Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2014 after selling out during the quarter.
  • Bessemer Group sold 4,455 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2014, an estimated $288K.
  • Bessemer Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 3 quarters.
  • Bessemer Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $288K in Q4 2013.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2014.

Based on Bessemer Group's 13F filing for Q1 2014, filed 14 May 2014.